^MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC (October 2009). "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". Journal of Medicinal Chemistry. 52 (19): 6012–6023.
doi:
10.1021/jm900712n.
PMID19791804.
^Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG (October 2016). "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology. 109: 148–158.
doi:
10.1016/j.neuropharm.2016.05.017.
PMID27267687.
S2CID19906601.
^Basu K, Mitra AK (1990). "Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone". International Journal of Pharmaceutics. 65 (1–2): 109–114.
doi:
10.1016/0378-5173(90)90015-V.
ISSN0378-5173.
^MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC (October 2009). "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". Journal of Medicinal Chemistry. 52 (19): 6012–6023.
doi:
10.1021/jm900712n.
PMID19791804.
^Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG (October 2016). "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology. 109: 148–158.
doi:
10.1016/j.neuropharm.2016.05.017.
PMID27267687.
S2CID19906601.
^Basu K, Mitra AK (1990). "Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone". International Journal of Pharmaceutics. 65 (1–2): 109–114.
doi:
10.1016/0378-5173(90)90015-V.
ISSN0378-5173.